The 81st Annual Meeting of the Japanese Society of Hematology

Presentation information

Oral Session

Oral Session 3-7A Multiple Myeloma: Daratumumab

Sun. Oct 13, 2019 9:00 AM - 10:00 AM No.7 (Tokyo International Forum, 5F Hall D5)

Chair: Noriko Nishimura (Dept. of Hematology, Oncology, The Cancer Institute Hospital, JFCR)

[OS3-7A-6] Daratumumab (DARA) subcutaneous (SC) vs intravenous (IV) administration in pts with RRMM: COLUMBA

Nizar J. Bahlis1, Maria-Victoria Mateos2, Hareth Nahi3, Wojciech Legiec4, Vladimir Vorobyev5, Ivan Spicka6, Vania Hungria7, Sibirina Korenkova8, Max Flogegard9, Joan Blade10, Philippe Moreau11, Martin Kaiser12, Shinsuke Iida13, Jacob Laubach14, Tahamtan Ahmadi15, Pamela L. Clemens16, Tara Masterson16, Kristen Lantz16, Lisa O‘Rourke16, Christoph Heuck16, Lixian Peng17, Dolly A. Parasrampuria16, Zhilong Yuan17, Ming Qi16, Saad Z. Usmani18 (1.University of Calgary, Arnie Charbonneau Cancer Research Institute, Calgary, AB, Canada, 2.University Hospital of Salamanca/IBSAL, Salamanca, Spain, 3.Karolinska Institute, Department of Medicine, Division of Hematology, Karolinska University Hospital at Huddinge, Stockholm, Kingdom of Sweden, 4.Department of Hemato-Oncology and Bone Marrow Transplantation, Medical University of Lublin, Lublin, Republic of Poland, 5.S.P. Botkin City Clinical Hospital, Moscow, Russian Federation, 6.General Faculty Hospital, Prague, Czech Republic, 7.Clinica São Germano, São Paulo, Federative Republic of Brazil, 8.Kiev Center for Bone Marrow Transplantation, Kiev, Ukraine, 9.Department of Internal Medicine, Falun General Hospital, Falun, Kingdom of Sweden, 10.IDIBAPS, Hospital Clinic de Barcelona, Barcelona, Spain, 11.University Hospital of Nantes, Nantes, France Metropolitan, 12.Division of Molecular Pathology, Institute of Cancer Research, Sutton, United Kingdom of Great Britain and Northern Ireland, 13.Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan, 14.Department of Hematology and Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States of America, 15.Genmab US, Inc., Princeton, NJ, United States of America, 16.Janssen Research & Development, LLC, Spring House, PA, United States of America, 17.Janssen Research & Development, LLC, Raritan, NJ, United States of America, 18.Levine Cancer Institute/Atrium Health, Charlotte, NC, United States of America)

Abstract password authentication.
Password is required to view the abstract. Please enter a password to authenticate.Password is written on a program book.

Password